GLSI News and Press, Greenwich LifeSciences Inc. From 12/18/20

Greenwich LifeSciences (GLSI) down 12.4% premarket on pricing upsized offering of 660K shares at $40/share, for gross proceeds of ~$26.4M (or ~$30.4M, if underwriters exercise their option in full).Underwriters' over-allotment is an additional 99K shares. Net proceeds will...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the pricing o...

Greenwich LifeSciences (GLSI) has entered into an option agreement with Westport Bio, to in-license a pre-clinical coronavirus vaccine program. In exchange for the option, the Company has agreed to sponsor research in an aggregate amount of up to $250k plus additional license and assignm...

Greenwich LifeSciences (GLSI) entered into an option agreement with Texas based, Westport Bio to in-license a pre-clinical coronavirus vaccine program that is currently at the stage of pre-clinical animal testing.In exchange for the option, the Company has agreed to sponso...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that it has e...

Gainers: BioCardia (BCDA) +102%.Arvinas (ARVN) +91%.Rubius Therapeutics (RUBY) +56%.Veru (VERU) +48%.AnPac Bio-Medical Science (ANPC) +45%.Homology Medicines (FIXX) +32%.ReneSola (SOL) +32%.Alexion Pharmaceuticals (ALXN) +31%.BioLineRx (BLRX) +30%.Big Rock Partners Acquisition (BRPA...

Gainers: Arvinas (ARVN) +97%, Rubius Therapeutics (RUBY) +95%, AnPac Bio-Medical Science (ANPC) +67%, Veru (VERU) +46%, BioCardia (BCDA) +31%.Losers: Aerpio Pharmaceuticals (ARPO) -47%, SELLAS Life Sciences (SLS) -27%, Greenwich Life...

Aerpio Pharmaceuticals ARPO -43% after announcing results from Razuprotafib Glaucoma Phase 2 Trial.Greenwich LifeSciences (GLSI) -18%.Gamida Cell (GMDA) -18% on providing regulatory update on biologics license application for Omidubicel.Virgin Galactic Holdings SPCE -...

Gainers: Sonoma Pharmaceuticals (SNOA) +87%.aTyr Pharma (LIFE) +65%.NantHealth (NH) +63%.vTv Therapeutics (VTVT) +55%.Equus Total Return (EQS) +45%Hancock Jaffe Laboratories (HJLI) +34%.MDJM (MDJH) +25%.Foresight Autonomous (FRSX) +23%.Solid Biosciences (SLDB) +22%.22...

Insider activity is getting increasingly informative to follow up during this tough market environment. Insider activity declined significantly in November, indicating that they believe the market is overvalued. However, one can still find very interesting stocks by following sign...